Regulatory Filings • Nov 9, 2012
Regulatory Filings
Open in ViewerOpens in native device viewer
Nantes & Lyon (France) – November 9, 2012 won first place in both the Deloitte Technology Fast 50 West same category. − VIVALIS (NYSE Euronext: VLS) announced today that it and NYSE Euronext listed companies in the
The Deloitte Technology Fast 50 Award was created in 1995 in San Jose, California, Valley, and soon spread throughout Netherlands, Israel, and France. It was created to highlight the exceptional contribution of technology companies to economic growth. the whole United States, then the United Kingdom, Canada, the in the heart of Silicon
For over 10 years, the award recognizes fast growing growing technology companies in their respective region region.
Franck Grimaud, CEO, and Majid Mehtali, CSO, co win both of the awards. These prizes years, the number of commercial licensees of our EB66® technology for the production of vaccines and antibodies has increased more than twofold. employee and entered a new market important partnership with Sanofi and expanded internationally with the opening enabled an increased revenue diversification and represent the basis of our future development around our three strategic axes: the EB66® cell line, the proprietary monoclonal antibody products possible." co-managers of VIVALIS, jointly stated recognize VIVALIS' development over the last five At the same time, we have more than doubled our market: the discovery of human monoclonal antibodies Pasteur. During the same period, we have completed a succe of a new subsidiary in Japan. These achievements have VIVA|Screen™ antibody discovery platform, and products. We would like to congratulate all our teams who made this managers stated, "We are honored to years. Over these five , number of antibodies, where we have an successful IPO, a portfolio of r
January 15 th, 2013, after NYSE Euronext market closing: 2013 Financial Calendar
Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell biotechnology and pharmaceutical industry for the manufacture o monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. Vivalis' expertise and intellectual property are leveraged in two main areas: Euronext: of vaccines and recombinant proteins, and develops cell-based solutions to the f
Customized solutions for the discovery, development and production of rare, fully human monoclonal offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical stage milestone payments along with royalties on net sales of licensed antibodies that are commercially developed from the use of the platform. monoclonal antibodies are
Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis ha partnerships and licenses with world leaders in biopharmaceutical industry, including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama. has established more than 30 s bio-
VIVALIS Listed on Euronext Paris Reuters: VLS.PA – Bloomberg: VLS FP Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes – Compartment C of NYSE Euronext
The Technology Fast 50 Award was created in 1995 in San Jose, California, (in the heart of Silicon Valley) and soon spread to the whole of the United States and then the United Kingdom, Canada, the Netherlands, Israel and France. The program is now operating in more than 40 countries and regions around the world. It was created to highlight the exceptional contribution of technology companies to economic growth.
Deloitte has in addition developed three continental rewards:
To know more: www.fast50france.com
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms. In France, Deloitte SA is the member firm of Deloitte Touche Tohmatsu Limited, and professional services are provided by its subsidiaries and affiliates. ng East ts quality rance, companies medium-sized enterprises. With the expertise of its 6,800
Deloitte provides audit, tax, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte bri class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte's approximately 193,000 professionals are committed to becoming the standard of excellence. brings world-
In France, Deloitte calls on diversified expertise to meet the challenges of its clients of all sizes from all industries major multinationals, local micro-companies and medium professionals and partners, Deloitte is a leading player in audit and risk services, consulting, financial advisory services, tax & legal and accounting, based on a multidisciplinary offering and a set of action principles attuned to the requirements of our environment. loitte sized
In Extenso, a member of Deloitte, is a major public accounting firm in France. Having a network of 3,800 employees and 185 branches throughout the country, In Extenso offers entrepreneurs, artisans, merchants, professionals, and association leaders a complete professional service with emphasis on proximity, listening, and pro-activity. Deeply rooted in the French economic fabric, In Extenso is the privileged contact of 80,000 clients in all sectors. In 2011 – 2012 the turnover of In Extenso was 270 million euros. For more information: www.inextenso.fr / www.reussir-auquotidien.fr
This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's Document de Référence, changes in economic conditions, the financial markets or the markets in which the company operates.
Franck Grimaud, CEO Financial communications agency Email: [email protected] Axelle Vuillermet / Pierre Laurent Tél.: +33 (0) 1 44 71 94 93 Email : [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.